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One Sentence Summary: Silencing key neurons with botulinum toxin conjugates 
exerts long-lasting pain relief in mouse models of chronic pain. 
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Abstract 
Chronic pain is a widespread debilitating condition affecting millions of people 
worldwide. Although several pharmacological treatments for relieving chronic pain 
have been developed, they require frequent chronic administration and are often 
associated with severe adverse events, including overdose and addiction.  Persistent 
increased sensitization of neuronal subpopulations of the peripheral and central 
nervous system has been recognized as a central mechanism mediating chronic pain, 
suggesting that inhibition of specific neuronal subpopulations might produce 
antinociceptive effects. We leveraged the neurotoxic properties of the botulinum 
toxin to specifically silence key pain processing neurons in the spinal cords of mice. 
We show that a single intrathecal injection of botulinum toxin conjugates produced 
long-lasting pain relief in mouse models of inflammatory and neuropathic pain 
without toxic side effects. Our results suggest that this strategy might be a safe and 
effective approach for relieving chronic pain while avoiding the adverse events 
associated with repeated chronic drug administration. 
 
 
 
INTRODUCTION 
Noxious stimuli of sufficient intensity to induce tissue damage leads to increased 
excitability of peripheral and central neuronal circuits that heightens pain experience 
and serves to protect damaged tissue from further trauma(1-4). In some cases 
ongoing disease or the failure of potentiated pain signaling networks to return to 
pre-injury levels leads to persistent or chronic pain conditions(5).  Persistent pain is 
highly prevalent and extremely difficult to treat (6, 7) with widely prescribed drugs 
such as opioids having significant unwanted side effects(7-9). While research into 
developing new analgesic drug therapies has been intense, translating knowledge 
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from preclinical observations in animal models to new therapies in the clinic has 
been challenging(6).  Research into the control of chronic pain states has however 
identified pathways connecting the spinal cord and brain that are key to the 
regulation of on-going pain states(10-13). Pioneering studies in rats and companion 
dogs(11, 14) showed that persistent pain states can be ameliorated by using a 
saporin-substance P conjugate to ablate a small population of spinal substance P 
receptor (NK1R) expressing projection neurons that convey pain-related information 
to the brain. In order to circumvent of the problem of killing spinal neurons with 
saporin, we designed botulinum conjugates that were safe to construct, non-toxic 
and acted relatively quickly after intrathecal injection to silence pain processing 
neurons in the spinal cord(15, 16).  
Botulinum toxin A is made up of a light chain zinc endopeptidase and a heavy chain 
that is responsible for binding the toxin to neuronal receptors and promoting 
essential light-chain translocation across the endosomal membrane(17).  Once 
internalized within the neuron, the light chain has the capacity to silence neurons for 
several months via the specific proteolytic cleavage of synaptosomal-associated 
protein 25 (SNAP25) a protein essential for synaptic release(15, 16, 18).  This 
inhibition is slowly reversed as the endopeptidase loses activity(17). cSNAP25 is 
found in neurons but not glial cells and is the unique substrate for botulinum 
protease cleavage(19, 20).  We exploited a recently introduced ‘protein stapling’ 
method(15, 18) using SNARE (Soluble N-ethylmaleimide sensitive factor Attachment 
protein Receptor complex) proteins to link the light chain/translocation domain 
(LcTd) of botulinum neurotoxin type A (BOT) to neurotransmitter ligands substance P 
and dermorphin that target pain processing neurons in the dorsal horn. In order to 
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silence NK1R-expressing neurons, we used a substance P-botulinum (SP-BOT) 
construct previously developed(15)  while mu opiate receptor expressing neurons 
were silenced using a dermorphin-botulinum construct.  We found that the new 
constructs were selectively internalized following binding to their target receptors, 
silenced neurons and produced a long-term amelioration of pain states. 
 
 
RESULTS 
SP botulinum conjugate induces long-term reduction of inflammatory and 
neuropathic pain sensitivity in mice. 
In order to silence NK1R-expressing neurons, we used a substance P-botulinum (SP-
BOT) construct previously developed (15). SP-BOT (Fig. S1) was injected intrathecally 
(i.t.) over the lumbar spinal cord of adult C57BL6/J male mice. Hind paw mechanical 
withdrawal thresholds measured with von Frey filaments were used as an indicator 
of analgesia. The i.t. injection of SP-BOT had no effect on baseline mechanical 
threshold in naïve mice tested over 7 days (Fig. 1A) and produced no signs of motor 
impairment assessed by plantar spreading or rotarod performance (Fig. 1B). 
However, in two models of inflammatory pain induced by ankle or hind paw 
injection of complete Freund’s adjuvant (CFA), i.t. injection of SP-BOT 2 days after 
CFA (when mice showed increased pain sensitivity) produced a substantial reduction 
in mechanical hypersensitivity that accompanied inflammation (Fig. 1C, D). One 
single i.t. injection was effective in reducing pain sensitivity  for the duration of the 
experiment (21 days for the ankle model and 12 days for the hind paw model). As 
internal control, in the hind paw model we showed that threshold of mechanical 
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allodynia  in the contralateral paw was unchanged (Fig.S2A).  Dose response 
experiments in animals that received an ankle injection of CFA showed that maximal 
reduction of pain sensitivity was obtained  with i.t injection of 100ng of SP-BOT (Fig. 
S3A).  
 
Intrathecal injections of the unconjugated BOT without a receptor-binding domain 
(Light-chain translocation domain, LcTd), had no effect on mechanical 
hypersensitivity following injection of CFA in the ankle (Fig. S4).  
 
We next investigated the effect of SP-BOT on neuropathic pain by testing the 
mechanical sensitivity in the unilateral (left) spared nerve injury (SNI) model of 
neuropathic pain (pain that is derived from peripheral nerve damage). The lesion 
induced hypersensitivity in the lateral area of the paw on the left side, which is 
innervated by the spared sural nerve. SP-BOT was injected i.t. when the mechanical 
hypersensitivity was fully developed and we observed a reduction in mechanical 
hypersensitivity that begun around 3d after SP-BOT injection and lasted for the 
duration of the experiment (22 days) (Fig. 1E).  Mechanical thresholds for the 
contralateral paw (right) were unchanged (Fig.S2B).  To confirm the essential role of 
NK1R in mediating the effects of SP-BOT induced reduction of mechanical pain 
sensitivity, we used NK1R knockout mice (NK1R-/-) (21) Neuropathic mechanical 
hypersensitivity was similar in NK1R-/- and wild type (WT) littermates after SNI. 
Intrathecal injection of SP-BOT was effective in alleviating mechanical 
hypersensitivity only in WT animals, whereas in NKRI-/- mice mechanical allodynia 
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was not affected by SP-BOT injection (Fig. 1F). The results indicate that the NK1R is 
essential for SP-BOT mediated reduction of mechanical pain hypersensitivity.  
 
SP-BOT is internalized only by NK1-receptor expressing neurons but does not cause 
cell death. 
The specificity of the targeted toxin was investigated by examining the distribution 
of cleaved SNAP 25 (cSNAP25) (Synaptosomal-associated protein of 25kDa) using 
immunohistochemistry in spinal cord tissue sections using an antibody specific for 
cSNAP25 (22). Tissue was taken from CFA-treated mice  that had received i.t. 
injections of SP-BOT, CFA-treated animals that received i.t saline injection and naïve 
animals (n=4 per group).  Double fluorescent immunohistochemistry for cSNAP25 
and NK1R indicated that the SP-BOT construct was expressed in cell bodies and 
axonal and dendritic branches of NK1R positive neurons(Fig. 2A, B). Cell bodies were 
first seen 96h after i.t. injection of the construct and the numbers and distribution of 
labelled cell bodies within the superficial dorsal horn remained unchanged for the 
duration of the experiment and was unaffected by peripheral treatment (Fig. S5). 
Analysis of the parabrachial nucleus (PB) of the hindbrain—the major site of 
termination of NK1R positive spinal projection neurons(23, 24)—revealed cSNAP25-
positive putative axons in all mice injected 14 days previously with i.t. SP-BOT, but 
not in saline-injected controls (Fig. 2C).  As NK1R is not found in axons(25), the 
results suggest that there had been axonal transport of cSNAP25 and/or botulinum 
protease following uptake of the SP-BOT conjugate by spinal NK1R positive dendrites 
and cell bodies. Immunohistochemistry measuring c-Fos expression, a marker of cell 
activity(26), showed that, in CFA injected mice, the activity of NK1R+ neurons had 
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been reduced in the parabrachial area of mice that had received an i.t. injection of 
SP-BOT 3 days previously, suggesting that SP-BOT successfully silenced NK1R+ cells 
(Fig. 2D). In naïve mice there was no evidence of microglial or astrocytic activation 
following SP-BOT treatment (Fig. S6).  Also, no changes in the extent of NK1R-
positive immunofluorescence were found in the dorsal horn of mice that had been 
treated with SP-BOT suggesting lack of construct-induced cytotoxicity or receptor 
down-regulation (Fig. 2E).  
 
Dermorphin-botulinum conjugate alleviates long-term pain states. 
Opioids such as morphine are effective in relieving chronic pain. Their analgesic 
properties are mostly mediated by the mu opioid receptor (MOR)(27) . In the dorsal 
horn MOR is expressed by interneurons and some primary afferents and by some 
projection neurons(28-30).   
To test the possibility that inhibiting MOR-expressing neurons could promote 
analgesic effects, we conjugated the botulinum toxin to the MOR agonist 
dermorphin (31, 32)(Derm-BOT) and compared the analgesic efficacy of Derm-BOT 
with morphine.  
 
Derm-BOT has been injected i.t at the optimal dose of 100ng/3ul  in naïve mice and 
in mice previously injected with CFA in the ankle joint or in the hind paw after 
increased mechanical pain hypersensitivity was established.   Derm-BOT injection did 
not affect mechanical pain sensitivity in naïve control mice (Fig. 3A); in contrast, we 
observed a reduction in the mechanical hypersensitivity that lasted until the end of 
the experiments (up to 18 days) in both models of inflammatory pain (Fig. 3B,C). 
 8 
Furthermore when Derm-BOT was injected after SP-BOT, the reduction in pain 
sensitivity induced by SP-BOT was not further augmented (Fig. 3D). We then 
investigated the effect of Derm-BOT on the hypersensitivity that develops after SNI 
surgery and found that a single i.t. injection of the construct alleviated the 
mechanical hypersensitivity for the duration of the experiment (23 days) (Fig. 3E).   
 
 
Dermorphin-botulinum conjugate was internalized by MOR positive neurons and 
did not induce toxicity.  
Immunohistochemical analysis of spinal cord sections from Derm-BOT injected mice 
showed that all cSNAP25-positive cell bodies and many neuronal processes 
throughout the dorsal horn were stained with MOR antibody (Fig. 4A, B) but there 
was no labelling of axons in the dorsal roots. Cell bodies were first seen 96h after i.t. 
injection of the construct and the numbers and distribution of cSNAP25 labelled cell 
bodies remained unchanged for the duration of the experiment (Fig. S5). These 
results indicated that cSNAP25 positive cell bodies and fibers were likely to be MOR-
positive local neurons (Fig. 4 A, B) and that MOR positive primary afferents did not 
internalize the construct.  We also failed to find evidence for glial activation in naïve 
mice treated with Derm-BOT (Fig. S6). As with SP-BOT, no indication of toxicity was 
found after Derm-BOT injection (Fig. S7).  
 
Dermorphin-botulinum conjugates replicate the analgesic actions of morphine  
Finally, we compared the effects on mechanical pain sensitivity of Derm-BOT with 
morphine (5nmol)(33) in the SNI mouse model. Intrathecal Derm-BOT reduced 
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mechanical sensitivity in SNI mice to the same extent as i.t. morphine  and no 
additive effects were seen when morphine was injected i.t into mice pre-treated 
with Derm-BOT (Fig. 5A).  This implied that pre-treatment with Derm-BOT silenced 
many of the MOR expressing neurons in the lumbar dorsal horn. Derm-BOT also 
generated analgesia in NK1R-/- mice (Fig. 5B) whereas SP-BOT was ineffective, 
confirming the specificity of the botulinum constructs.  
DISCUSSION 
There is an urgent need for new pain-relieving therapies(34). Here we used animal 
models of inflammatory and neuropathic pain to show that a single injection of 
compounds derived from botulinum toxin can silence pain-processing neurons in the 
spinal cord and decrease pain hypersensitivity.  In two sets of experiments we 
targeted NK1R expressing neurons that relay pain-related information from the 
spinal cord to the brain and the MOR-expressing spinal cells that modulate activity of 
NK1R-expressing output neurons(10, 30, 35).   We describe a long-term effect on 
mechanical pain sensitivity on both inflammatory and neuropathic pain states, 
following a single injection of the constructs and demonstrate in vivo receptor 
specificity. We found no additive effects of SP-BOT and Derm-BOT, suggesting that 
although the constructs silence different neurons, they are likely to be part of the 
same neural pain network with MOR-expressing excitatory neurons modulating 
NK1R positive projection neurons. As such these new botulinum constructs would 
appear to be equally useful in reducing pain hypersensitivity . 
 
Among the seven types (A-G) of botulinum toxin that target neurons, due to its long-
lasting activity and high efficiency, Botulinum toxin serotype A (BoNT/A) has been 
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approved by the FDA for treating a variety of disorders(36-40). In neuronal cultures, 
the proteolytic activity of BoNT/ persists beyond 80 days whereas other subtypes of 
BoNT have shorter half-lives(37, 41). Peripheral injections of botulinum neurotoxins 
have been shown to reduce both neuropathic pain and the frequency of migraine 
attacks in human patients(42-44). This anti-nociceptive action has been exploited by 
a number of groups(44, 45);more recently, using a synthetic procedure it was 
possible to separate the pain relieving from the paralyzing actions by synthesizing 
peptide components of BoNT/A and ‘re-stapling’ them into a unique 
configuration(15, 16). Systemic administration of these reassembled molecules was 
shown to inhibit neuronal activity without causing toxicity (18). To generate the 
botulinum-based molecules we used a synthesis procedure that allowed non-
chemical linking of recombinantly produced proteins using core components of the 
SNARE complex to achieve irreversible linkage of two separate peptide fragments 
into a functional unit(16). This approach was particularly important as the 
production of functional botulinum-based molecules has significant safety issues due 
to protein toxicity. The assembly of the functional toxin from innocuous parts is 
therefore an important advance as safety issues have severely restricted the 
development of botulinum-derived molecules for medical use.  
We generated new molecules by substituting the non-specific neuronal binding 
targeting domain of BoNT/A with ligands that recognize the key G protein-coupled 
neurotransmitter receptors NK1R and MOR. Binding to these receptors was followed 
by internalization of the construct and, because of the inclusion of the translocation 
domain into our constructs, release of the protease domain of the toxin into the 
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cytoplasm and inhibition of synaptic release. The synthesis of SP-BOT has been 
previously described (15) but to synthesize the Derm-BOT construct required further 
synthetic steps. Dermorphin is a potent selective opioid mu receptor agonist (31, 32, 
46)and has been successfully used previously in saporin conjugates to 
selectively ablate MOR-expressing neurons(13).  Conjugation of dermorphin to the 
LcTd portion of botulinum was complicated because dermorphin binds to the 
receptor through its N-terminus, the portion of the molecule generally used for the 
botulinum conjugation procedure(16).  To circumvent this problem we introduced a 
synthetic inversion procedure (see Methods) that allowed conjugation of 
dermorphin to the LcTd portion of botulinum toxin while retaining the free N-
terminus of dermorphin for binding to the mu opiate receptor, followed by 
internalization and SNAP25 cleavage. 
  It is likely that the separation of the botulinum translocation domain from the 
neuropeptide ligands using the ‘stapling’ mechanism allowed sufficient freedom for 
the translocation domain to perform the pH-dependent structural transition 
necessary to facilitate transfer of the botulinum protease from the luminal space of 
vesicle into the neuronal cytosol. However, it has been reported(47) that attachment 
of SP directly to botulinum protease allowed entry into neurons and SNAP25 
cleavage.  Omission of the obligatory translocation domain from the construct 
suggests that the activity would have been suboptimal and may account for the 
short in vivo efficacy(47).  
  
SNAP25, the unique substrate for botulinum peptidase activity, is found throughout 
dendrites, where a role in spine morphogenesis has been proposed (48), as well as in 
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cell bodies and axons. NK1R receptors are located on dendrites and cell bodies while 
MOR is also found on axons and axon terminals and binding and internalization 
would be expected at most receptor binding sites(25, 49, 50). Given the lack of 
axonal NK1R expression, the presence of cleaved cSNAP25 in spinal to brainstem 
axons following spinal treatment with SP-BOT was most likely the result of cleavage 
of SNAP25 in NK1R-positive dendrites and cell bodies in the dorsal horn followed by 
axonal transport of cSNAP25 and/or the protease to the synaptic terminals within 
the brainstem.   
NK1R expressing spinal projection neurons have been shown to be essential for the 
maintenance of pain states (11).  Information related to injury reaches the brain 
largely through NK1R-positive projection neurons of the superficial dorsal horn that 
terminate massively in the parabrachial area of the brainstem and to a lesser extent 
within the thalamus(35, 51). The parabrachial area is crucial for supplying 
information to forebrain areas that generate the affective-motivational component 
of pain(52, 53) whereas thalamic afferents terminate within cortical areas concerned 
with both pain discrimination and affect(51). Forebrain activation can in turn 
regulate dorsal horn sensitivity by activating descending controls from the brainstem 
to the spinal cord (3, 12, 54). Thus a shift in the balance between pain inhibiting and 
facilitating controls from the brainstem, informed by NK1R-positive dorsal horn 
projection neurons, plays a role in setting spinal nociceptive thresholds required by 
on-going behavioural priorities and may ultimately contribute to pathological pain 
states(54). It follows that the inflammatory and neuropathic mechanical allodynia is 
disrupted by intrathecal ablation or silencing of these NK1R-expressing projection 
neurons with substance P-saporin (11) or SP-BOT constructs respectively.  Recent 
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work has shown that chemotoxic ablation of the NK1R-positive pain pathway in 
companion dogs can relieve bone cancer pain(14) demonstrating the applicability of 
the approach to higher mammals in different pain subtypes. 
 
The disadvantage of the substance P-saporin procedure is that it takes several weeks 
to become effective and kills neurons(11, 14). Our intention was to design a 
reversible and non-toxic molecule that would achieve the same analgesia, rapidly 
and without cell death. The approach described here using SP-BOT silences NK1R 
expressing neurons without cell death and is effective in days rather than weeks; in 
addition, SP-BOT  is relatively easy to synthesize. As expected the analgesic effect of 
SP-BOT constructs was completely lost in NK1R knockout mice.  
 
MOR is expressed by dorsal horn interneurons and found in some small diameter 
primary afferent sensory fibers(49, 55, 56). However, previous research has implied 
that the opioid tolerance and opioid-induced hyperalgesia that follow repeated 
injections of morphine are mediated by primary afferent MORs(55).  It was also 
shown that i.t. morphine produced strong mechanical and thermal antinociception 
in naive mice but that was lost in mice in which MOR had been deleted only from 
primary afferents(55) suggesting that spinal neurons expressing mu opiate receptors 
did not play a role in setting baseline mechanical thresholds or the generation of 
analgesic tolerance following repeated injections of morphine. However, intrathecal 
Derm-BOT in the naïve mice reported here, had no effect on baseline mechanical 
pain sensitivity but only on mechanical thresholds in injury-induced pain states.  This 
suggests that the target for Derm-BOT mediated analgesia was not primary afferents 
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expressing MOR, but MOR positive dorsal horn neurons.  A similar result was 
reported in rats following the partial ablation of MOR expressing neurons with 
dermorphin-saporin (Derm-SAP) conjugates(57) raising the possibility that 
presynaptic opiate receptors may not internalise after opiate agonist 
administration(58).  
Currently, new approaches to the control of chronic pain have adopted both central 
intrathecal and peripheral systemic approaches. Intrathecal opioids and other drugs 
are often given in clinical practice to relieve chronic pain when other treatment 
routes are exhausted or to circumvent the inherent risks of long-term systemic 
opioid treatment. However, intrathecal administration requires a surgically-
embedded pump to administer a prolonged infusion of the drug to the spinal 
cord(59, 60). Intrathecal treatments primarily target and inhibit central sensitization, 
the driving force behind chronic pain states. Unfortunately, long-term intrathecal 
opioid administration can result in respiratory depression, i.t. granuloma, opioid 
tolerance and other serious side effects(61).  Moreover, although systemic opioids 
remain the gold standard for pain control, there are major concerns around the 
problems of drug overdose and addiction in part due to the relaxation of prescribing 
of opioids for non-terminal chronic pain(9). Conjugates of the silencing domain of 
botulinum toxin with SP or dermorphin provide substantial analgesia without 
evident toxic effects and over long periods of time following a single i.t. injection. 
Complete analgesia is not entirely desirable. As clinical studies with anti-nerve 
growth factor antibodies have demonstrated encouraging the use of an already 
damaged limb may have resulted in further damage leading to hip or knee 
replacement(62, 63). The successful use of SP-saporin in rodents and dogs also 
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opens up the possibility that silencing of this pathway with SP-BOT might be 
sufficient to control chronic pain states in human patients without permanent 
damage to the spinal cord(11, 14).  
Also, the side effects of chronic opioid use including analgesic tolerance, paradoxical 
opioid-induced hyperalgesia and addiction(64) might be avoided by a single 
intrathecal injection of the dermorphin-botulinum construct.  
Translating knowledge from preclinical observations in animal models of pain states 
to new therapies in the clinic has been difficult and has met with limited success. 
Differences between animal behavioural tests and human chronic pain features, 
particularly the assessment of both sensory and affective features of the pain state, 
as well as measurements of long-term efficacy and species variability may have been 
confounding factors(6).  Nevertheless the successful translation of the substance P-
saporin treatment from rats to companion dogs with bone cancer pain suggests(11, 
14) there is potential for the introduction of botulinum-based silencing approaches 
for the control of pain without cytotoxicity or recourse to repeated treatment of 
analgesics that can produce adverse behavioural effects. 
 
 
METHODS  
Study Design 
This study was designed to evaluate the effect of SP-BOT and Derm-BOT on pain 
sensitivity. In behavioural studies, mice were randomly assigned to experimental 
groups. The experimenter was always blind to treatment and genotype. We could 
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not predict a priori the effect size for the botulinum constructs and were guided by 
Mead’s Resource equation. Therefore, we aimed to use at least 6 mice in each group 
and no more than 11. Occasionally mice were excluded from the study if they were 
found to have bodily damage from fighting with cage mates (5 out of 206 total mice 
were discarded). We did perform statistical analysis at the end of each round of 
experiments in order to satisfy the 3Rs which dictates that “The number of animals 
used should be the minimum number that is consistent with the aim of the 
experiment” (https://www.nc3rs.org.uk/the-3rs).  
 
Mice 
Subjects in all experiments were adult mice (8–12 weeks old). Wild-type (WT) mice 
were C57BL/6 from Envigo.  NK1R KO (NKR1-/- ) and WT littermates were obtained 
from a colony of mice derived from a 129/Sv × C57BL/6 genetic background(21). 
NKR1-/- mice were backcrossed with a wild type C57/B6 mouse for several 
generations. Experiments were always carried out using  littermates from 
heterozygous breeding pairs. All mice were kept in their home cage in a 
temperature-controlled (20 ± 1˚C) environment, with a light-dark cycle of 12 h (lights 
on at 7:30 a.m.). Food and water were provided ad libitum. All efforts were made to 
minimize animal suffering and to reduce the number of animals used (UK Animal Act, 
1986).  
 
Genotyping 
For genotyping, DNA was extracted from ear tissue, and the following primers were 
used for PCR: forward NK1R primer, CTGTGGACTCTAATCTCTTCC; reverse NK1R 
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primer ACAGCTGTCATGGAGTAGATAC; Neomycin-resistant gene (NeoF) primer 
GCAGCGATCGCCTTCTATC. Samples from WT mice showed a single PCR (Polymerase 
Chain Reaction) product of 350 base pairs (bp); samples from NKR1-/- mice showed a 
single PCR product of 260 bp; and samples from heterozygous mice would present 
both bands(21).  
 
Design and purification of botulinum constructs 
Each BoNT/A consists of three domains: the binding domain (Bd), the translocation 
domain (Td), and the catalytic light-chain domain (Lc), a zinc metallopeptidase. We 
utilized a protein stapling technique to produce light chain and translocation domain 
(LcTd) conjugated to substance P or dermorphin, a naturally occurring mu-opioid 
agonist which carries an unnatural D-amino acid, making it resistant to internal 
proteolysis. The synthesis has been described previously for SP with in vitro controls 
for specificity detailed(15).  Briefly, to synthesize the constructs:  
a) a fusion protein consisting of the LcTd of the botulinum type A1 strain was fused 
to SNAP25 (LcTd-S25) and was prepared as previously described(16, 65). The 
chemically synthesised syntaxin-SP peptide had the sequence:  
Ac-EIIKLENSIRELHDMFMDMAMLVESQGEMIDRIEYNVEHAVDYVE-Ahx-Ahx-
RPKPQQFFGLM-NH2, where Ahx stands for aminohexanoic acid.  Due to the need for 
the N-terminus of dermorphin to be accessible for binding to the MOR, the syntaxin-
dermorphin peptide was synthesized in two parts, syntaxin-maleimide and 
dermorphin-cysteine, which were then bio-orthogonally conjugated through two 
reactive C-termini. The dermorphin and syntaxin sequences were respectively: 
YaFGYPS and EIIRLENSIRELHDMFMDMAMLVESQGEMIDRIEYNVEHAVDYVEK.  
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b) The protein ‘staple’ was prepared recombinantly from the rat VAMP2 sequence 
(aa 3-84) inserted into the XhoI site of pGEX-KG. Oriented attachment of peptides to 
protein was achieved by the SNARE assembly reaction. LcTd-S25, VAMP2 (3-84) and 
either syntaxin-dermorphin or syntaxin-SP were mixed at a molar ratio of 1:1:1 in 
100 mM NaCl (Sodium Chloride), 20 mM HEPES (4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid) and 0.4% n-octylglucoside (OG), at pH 7.4 (Buffer A). 
Reactions were left at 20°C for 1 hour to allow formation of the SNARE ternary 
complex. Sodium dodecyl sulfate (SDS)-resistant and irreversibly assembled protein 
conjugates were visualised using Novex NuPAGE 12% Bis-Tris SDS–PAGE 
(Polyacrylamide Gel Electrophoresis) gels (Invitrogen) run at 4°C in NuPAGE MES SDS 
running buffer (Invitrogen). All recombinant proteins were expressed in the BL21-
Gold-PLysS-DE3 strain of Escherichia coli (Agilent) in pGEX-KG vectors as glutathione-
S-transferase (GST) C-terminal fusion proteins cleavable by thrombin. GST fusion 
constructs were purified by glutathione affinity chromatography and cleaved using 
thrombin. Synthetic peptides were made by Peptide Synthetics, Ltd. 
 
Cortical cultures 
To confirm construct efficacy rat cortical neurones were dissected from 8–12 
embryonic day 17 rat pups and washed in Hanks' Balanced Salt Solution (HBSS), 
before being treated with trypsin for 15 min at 37°C, followed by addition of DNase 
(Sigma). Cells were resuspended in 1 ml triturating solution (1% Albumax (Gibco), 0.5 
mg/mL Trypsin inhibitor (Sigma), 1 µg/mL DNase in HBSS). Cells were triturated using 
three progressively smaller glass pipettes before being diluted to 5ml by the addition 
of cortical medium. 50,000 cells in 150µl medium were plated on 96-well plates 
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coated with poly-D-lysine. Cells were maintained in neurobasal medium (Gibco) 
supplemented with 1% B27 (Gibco), 1% P/S, and 1% GlutaMAX (Gibco)) Half the 
medium was changed every 3–4 days and cultures were tested between 1 and 3 
weeks after plating. 
 
Western analysis of botulinum activity 
Derm-BOT and SP-BOT (400 nM in Buffer A (100 mM NaCl, 20 mM HEPES)) were 
added to the plated cortical cells at a 1:20 dilution to achieve the final concentration 
of 20 nM. Cells were incubated at 37°C and 5% CO2 for 65 h before culture media 
was removed and 20 µl of loading buffer (56 mM sodium dodecyl sulfate, 0.05 M 
Tris-HCl, pH6.8, 1.6 mM UltraPure EDTA (Gibco), 6.25% glycerol, 0.0001% 
bromophenol blue, 10 mM MgCl2, 26 U/mL benzonase (Novagen)) was added to 
each well. Plates were shaken at 900 rpm for 10 min at 20°C and samples were 
transferred to a fresh 0.5 ml tube. Samples were boiled for 3 min at 95°C and then 
run on Novex NuPAGE 12% Bis-Tris SDS–PAGE gels (Invitrogen). Following 
separation, proteins were transferred onto immobilin-P polyvinylidene difluoride 
membranes, and then incubated for 30 min in blotting solution (5% milk, 0.1% 
TWEEN 20 in PBS). Mouse monoclonal SMI81 antibody (anti-SNAP25) was added at 
1:2000 dilution to the blotting solution at 4°C for overnight incubation. Membranes 
were washed three times in 0.1% TWEEN 20 in PBS for 5 min and then incubated for 
30 min in the blotting solution containing secondary peroxidase-conjugated donkey 
anti-rabbit antibody (Amersham) at a 1:2400 dilution. Membranes were washed 
three times for 5 min in 0.1% TWEEN 20 in PBS. Immunoreactive protein bands were 
visualized using SuperSignal West Dura Extended Duration solution (Thermo 
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Scientific, Cramlington, UK) with exposure to Fuji Medical X-ray films (Fuji, Ross-on-
wye, UK). 
 
Behavioural testing 
Von Frey filament test 
The experimenter was always blind to genotype and treatment group for all 
behavioural tests. Animals were placed in Plexiglas chambers, located on an elevated 
wire grid, and allowed to habituate for at least 1 hour. After this time, the plantar 
surface of the paw was stimulated with a series of calibrated von Frey’s 
monofilaments. The threshold was determined by using the up-down method(66) 
The data are expressed as log of the mean of the 50% pain threshold ± SEM. In some 
cases the data was plotted as force (g) (Fig S8 and S9). 
 
Rotarod test 
Motor performance was evaluated by an accelerating rotarod apparatus with a 3-
cm-diameter rod starting at an initial rotation of 4 rpm and slowly accelerating to 40 
rpm over 100 s. Mice were expected to walk at the speed of rod rotation to keep 
from falling. The time spent on the rod during each of two trials per day was 
measured and expressed in seconds. Animals were tested only once at baseline to 
minimize the number of tests on the rotarod. Testing was completed when the 
mouse fell off the rod (that is, from a height of 12 cm). 
 
 
Pain models 
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Mouse inflammatory models 
CFA-induced ankle joint inflammation 
Inflammation was induced by injection of 5 μl of Complete Freud’s Adjuvant (CFA; 
Sigma) into the left ankle joint under isoflurane anaesthesia induced in a chamber 
delivering 2% isoflurane combined with 100% O2 and maintained during injection via 
a face mask. The needle entered the ankle joint from the anterior and lateral 
posterior position, with the ankle held in plantar flexion to open the joint(67).  
CFA-induced hind paw inflammation 
CFA (20 μl) was injected using a micro-syringe with a 27-gauge needle 
subcutaneously into the plantar surface of the left hind paw. Mice were maintained 
under isoflurane anaesthesia during the injection. 
 
Mouse neuropathic model: spared nerve injury  
The spared nerve injury (SNI) was performed as previously described(68). Briefly, 
under isoflurane anaesthesia the skin on the lateral surface of the thigh was incised 
and a section made directly though the biceps femoris muscle, exposing the sciatic 
nerve and its three terminal branches: the sural, the common peroneal and the tibial 
nerves. The common peroneal and the tibial nerves were tight-ligated with 5-0 silk 
and sectioned distal to the ligation. Great care was taken to avoid any contact with 
the spared sural nerve. Complete hemostasis was confirmed and the wound was 
sutured.  
 
Intrathecal injections 
 22 
Intrathecal injections were performed under anaesthesia(69). The mice were held 
firmly, but gently, by the pelvic girdle using thumb and forefinger of the non-
dominant hand. The skin above the iliac crest was pulled tautly to create a horizontal 
plane where the needle was inserted. Using the other hand, the experimenter traced 
the spinal column of the mouse, rounding or curving the column slightly to open the 
spaces between vertebrae. A 30-gauge needle connected to a 10 μl Hamilton syringe 
was used to enter between the vertebrae. After injection, the syringe was rotated 
and removed and posture and locomotion were checked. All intrathecally delivered 
drugs were injected in a 3 μl volume. 
 
Immunohistochemistry 
Mice were deeply anesthetized with pentobarbital and perfused transcardially with 
physiological saline containing 5000 IU/ml heparin followed by 4% 
paraformaldehyde (PFA) in 0.1 M phosphate buffer (PB; 25ml per adult mouse). 
Lumbar spinal cords were dissected out, fixed in 4% PFA for an additional 2 h, and 
transferred into a 30 % sucrose solution in PB containing 0.01% azide at 4°C, for a 
minimum of 24 h. Spinal cord sections were cut on a freezing microtome set at 
40 μm. For fluorescent immunohistochemistry, sections were left to incubate with 
primary antibodies O/N at room temperature (anti-cSNAP25 antibody recognizing 
the cleaved end of SNAP25 1:50,000 ref, TRIDEANQ; anti-NK1, guinea pig, 1:10,000, 
Neuromics; anti-MOR, rabbit, 1:10,000, Neuromics). For NK1 and MOR 
immunohistochemistry, direct secondary antibody was used at a concentration of 
1:500 (Alexa Fluor). For cSNAP25 staining, appropriate biotinylated secondary 
antibody was used at the concentration of 1:400 and left for 90 min. Sections were 
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then incubated with avidin-biotin complex (ABC Elite, Vector Lab; 1:250 Vectastain A 
plus 1:250 Vectastain B) for 30 min followed by a signal amplification step with 
biotinylated tyramide solution (1:75 for 7 min; Perkin Elmer). Finally, sections were 
incubated with FITC-avidin for 2 h (1:600). An antibody against Iba1 (Ionized calcium 
binding adaptor molecule 1, Goat, 1:500 overnight, Abcam) was used to identify 
microglia and an anti-GFAP antibody to stain for astrocytes (Glial fibrillary acidic 
protein, rabbit, 1:4000, overnight, Dako) using immunohistochemistry.  The direct 
secondary antibody was used at a concentration of 1:500 (Alexa Fluor). All 
fluorescent sections were transferred to glass slides and cover slips applied with Gel 
Mount Aqueous Mounting Medium (Sigma) to prevent fading, and stored in dark 
boxes at 4°C. In co-labelling studies, controls included omission of the second 
primary antibody. 
 
Quantification of fluorescence  
For quantification of NK1R- and MOR-fluorescence, a region of interest (ROI) was 
located over laminae I/II. The ROI was 3087 μm2 for NK1R and 1617 μm2 for MOR 
immunostained tissue.     Fluorescence was measured for six sections per animal 
using the same ROI. Readings were taken from the side of the spinal cord 
contralateral to the inflamed paw or nerve lesion.  Contrast enhancement and 
fluorescence threshold were kept constant. Readings from saline and botulinum 
construct i.t. injected mice were compared. 
 
c-Fos immunohistochemistry 
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c-Fos immunohistochemistry was used to assess the silencing of the lamina 1 NK1R 
positive neurons.  Preemptive i.t. treatment with SP-BOT in naïve mice was followed 
3 days later by an injection of CFA into the left paw under isoflurane anaesthetic. 6h 
later animals were perfused and processed for c-Fos expression in the lateral 
parabrachial area. For DAB ( 3,3’ – Diaminobenzidine), sections were blocked in PB 
with 3% serum, 3% triton and 2% H2O2 for one hour, and then incubated over 
weekend with the primary antibody (anti c-Fos, rabbit, 1:10000, Millipore Merck 
KGaA). The sections were then incubated in appropriate secondary antibody at 1:500 
for 2 hours, followed by incubation with avidin biotin complex (ABC Elite, Vector Lab; 
1:1000 Vectastain A plus 1:1000 Vectastain B) for 1 hour. The substrate was then 
developed using a peroxidase substrate DAB kit (Vector #SK4100) at optimised 
times, and the sections were washed and mounted. The following day, the sections 
were dehydrated in increasing ethanol concentrations (70%, 70%, 95%, 95%, 100%, 
100%, histoclear x2) and coverslipped with DPX. 
Five sections through the PBN from each mouse were analysed for population 
density of c-Fos neurons. cFos-immunoreactive neurons were counted in the lateral 
parabrachial area bilaterally.  Counts from the sections were averaged and the mean 
was used for further statistical analysis. To quantify cSNAP positive neuronal cell 
bodies 4 spinal cord sections from each mouse were counted.  Means were taken for 
each treatment for further analysis.  Counts were from laminae I-III of the dorsal 
horn. 
 
Statistical analysis 
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All statistical tests were performed using the IBM SPSS statistics programme, version 
20, and P<0.05 was considered statistically significant. For the behavioural 
experiments, statistical analysis was performed on the data normalized by log 
transformation (von Frey data) as suggested by Mills et al.,(70) Difference in 
sensitivity was assessed using repeated-measured two-way or one-way analysis of 
variance (ANOVA), as appropriate and as indicated. In all cases, a significant effect of 
the main factor(s), or interactions between them, was taken as the criterion for 
progressing to post hoc analysis. Bonferroni correction was the preferred post hoc 
approach, when we had 3 groups or more; in this case, if the general ANOVA was 
significant but no Bonferroni significance observed, we also reported the results of 
the least significant difference post hoc analysis. When we had 2 groups, we report 
the result of the one-way ANOVA. In all cases ‘time’ was treated as a within-subjects 
factor, and ‘genotype’ and ‘treatment’ were treated as between-subject factors. The 
statistical significance in fig 2D was determined using one-way ANOVA followed by 
LSD (Fisher’s Least Significant Difference)  test. 
 
The Maximum Possible Effect (MPE) was calculated as: 
 
%MPE=    100*[log(drug induced threshold) – log(vehicle induced threshold)] 
[log(0,6) – log(vehicle induced threshold)] 
 
Where log (0.6g) is our maximum Von Frey’s force applied. 
Please note that, as in our previous paper (67), we logged the data of the 
behavioural testes to ensure a normal distribution since the Von Frey’s hairs are 
distributed on an exponential scale. Mills et al, 2012, recently demonstrated that Log 
transformation makes more ‘mathematical and biological sense’ (62). 
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Fig 1: SP-BOT administered intrathecally (i.t.) reduced the mechanical 
hypersensitivity that developed in long-term inflammatory and neuropathic pain 
states. A) Mechanical threshold assessed using von Frey filaments in naïve mice 
before (B1) and 1–7 days (D1 to D7) after i.t. injection of SP-BOT (100ng/3l n=4 per 
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group). (B) Time on rotarod apparatus after SP-BOT i.t. injection (n=4 per group) (C) 
Von Frey filaments were used to measure mechanical hypersensitivity in mice 
injected with 5lof Complete Freund’s Adjuvant (CFA) in the ankle joint and 3 days 
later injected with i.t. SP-BOT (100ng/3l). Mice were tested at baseline and up to 21 
days after CFA injection (n=5-6 per group). (D) CFA (20l) was also injected into the 
plantar surface of the hindpaw, and 4 days later mice received i.t. SP-BOT 
(100ng/3l; n=7 per group). (E) SP-BOT was injected i.t. 5 days after spared nerve 
injury (SNI) and alleviated the neuropathic mechanical sensitivity that had developed 
(n=8 per group). (F) NK1R knockout mice and their wild-type littermates received i.t. 
SP-BOT 5 days after SNI (n= 8 per group). Data show means  SEM (Standard Error of 
the Mean). (D: Day) *P < 0.05, **P < 0.01, ***P < 0.001. Difference in sensitivity was 
assessed using repeated-measured two-way followed by one-way ANOVA. For 
complete statistical analyses, please refer to Supplementary Table 1 and for 
maximum possible effect (%MPE) please refer to Supplementary Table 2. 
 
Fig 2: SP-BOT was internalized by NK1R-positive neurons without toxicity. (A) 
Images of NK1R and cSNAP25 immunoreactivity in the superficial dorsal horn of mice 
14d after i.t. injection of SP-BOT. Green, cSNAP25; red, NK1R. Scale bar 100m. (B) 
Images of selective targeting of NK1R expressing neurons in the superficial dorsal 
horn 96h (top) or 14d (bottom) after i.t. injection of SP-BOT. Green, cSNAP25; red, 
NK1R. Scale bar top row 20m, bottom rows 10m. (C) Schematic illustration and 
images of the lateral parabrachial area (LPb) of mice 25 days after the i.t. injection of 
SP-BOT or saline. cSNAP25 in spino-parabrachial axons in green. Scale bar 80m. 
DRG: dorsal root ganglia (D) Bar graph illustrating the number of cFos-
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immunostained nuclei in the PB from both saline and SP-BOT injected mice. Mice 
received i.t. SP-BOT and 3 days later they were injected with CFA into the plantar 
surface of the hind paw. Tissue was taken 6h later. Values reported are the mean 
number of c-Fos+ nuclei ( SEM) normalized to the mean of c-Fos+ nuclei in naïve 
control mice (n= 4 per group). (E) Quantification of NK1R fluorescence intensity in 
the contralateral superficial dorsal horn of mice 18d after intraplantar CFA injection 
and 14 days after i.t. injection of SP-BOT or saline. All data were normalized to 
laminae I/II saline-treated mice (n=4 per group). *P < 0.05 The comparison of three 
groups was determined using one-way ANOVA. 
 
Fig 3: Derm-BOT  reduced the mechanical hypersensitivity in inflammatory and 
neuropathic pain models in mice.   (A) Mechanical threshold assessed using von 
Frey filaments in naïve mice before (B1) and after (Day1 to Day7 (D1 – D7)) i.t. 
injection of Derm-BOT (100ng/3l n=4 per group). (B) Mechanical threshold was 
measured in mice before and after CFA injection (5l) in the ankle joint. 4 days later 
mice were injected i.t. with Derm-BOT (100ng/3l). Mice were tested at baseline and 
up to 14 days after CFA injection (n=5 per group). (C) CFA (20l) was injected into 
the plantar surface of the hind paw and 4 days later mice received i.t. Derm-BOT 
(100ng/3l; n=8 per group). (D) Mechanical threshold measured using von Frey 
filaments in mice injected with CFA (5l) in the ankle joint and 3 days later injected 
with i.t. SP-BOT (100ng/3l). 2 weeks later mice injected with SP-BOT were re-
injected with i.t. Derm-BOT (n=4 per group).  (E) Derm-BOT was injected i.t. in mice 5 
days after SNI surgery (n=9 per group). Data show means ± SEM. *P < 0.05, **P < 
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0.01, ***P  0.001. Difference in sensitivity was assessed using repeated-measured 
two-way followed by one-way ANOVA.  
 
Fig 4: Derm-BOT was internalized by MOR expressing neurons. (A) Images of 
cSNAP25 and MOR immunoreactivity in the superficial dorsal horn of mice 14d after 
injection of i.t. Derm-BOT. Green, cSNAP25; red, MOR. Scale bar 100m. (B) Images 
of selective targeting of cSNAP to MOR expressing neurons in the superficial dorsal 
horn 96 h (top and bottom row) or 14d after i.t. injection of Derm-BOT. Green, 
cSNAP25; red, MOR. Scale bar top row 20m, middle and bottom row 10m. 
 
Fig 5: Derm-BOT preclude the effect of morphine and retains efficacy in NK1R 
knockout mice. (A) Mechanical threshold using von Frey filaments in mice injected 
i.t. with Derm-BOT 5 days after SNI surgery. 29 days later mice were injected with i.t. 
morphine (5nM, n=9 per group).  (B) Mechanical threshold measured using von Frey 
filaments in NK1R knockout mice before and after SNI surgery. 5 days after surgery 
mice were injected with i.t. SP-BOT and 2 weeks later were injected with i.t. Derm-
BOT (n=8 per group). Data show means  SEM. *or #P < 0.05, **P < 0.01, *** or ### P 
 0.001. Difference in sensitivity was assessed using repeated-measured two-way 
followed by one-way ANOVA.  
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